|Bid||61.00 x 100|
|Ask||65.50 x 200|
|Day's Range||60.85 - 62.90|
|52 Week Range||28.35 - 136.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.00|
Puma Biotechnology, Inc. , a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® in Argentina, Brazil, Chile, Colombia, Mexico and the rest of Latin America.
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced today that NERLYNX® has been included as a recommended treatment option in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Central Nervous System Cancers for Breast Cancer patients with brain metastases.
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
I am going to run you through how I calculated the intrinsic value of Puma Biotechnology Inc (NASDAQ:PBYI) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Litigation:
Examining Puma Biotechnology Inc’s (NASDAQ:PBYI) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m.
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
The Los Angeles-based company said it had a loss of $1.71 per share. Losses, adjusted for stock option expense, were $1.03 per share. The results topped Wall Street expectations. The average estimate of ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2017, compared to the fourth quarter and full year 2016.
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Puma Biotechnology, Inc. (NASDAQ: PBYI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 4:30 PM Eastern Time. ...
Stock Monitor: BioMarin Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Puma Biotechnology, Inc. (NASDAQ: PBYI ...
KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.
Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion, recommending the refusal of the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunCoke ...
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 1, 2018 following release of its fourth quarter and full year 2017 financial results.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Puma Biotechnology, Inc. , a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an exclusive agreement under which CANbridge will develop and commercialize NERLYNX® in mainland China, Taiwan, Hong Kong, and Macau .
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT Phase II ‘basket’ clinical trial of PB272 in patients with tumors harboring HER2 or HER3 mutations were published in the journal Nature.